Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECT: Lanreotide for Carcinoid Syndrome
NCT00774930Phase 3Completed
- Sponsor
- Ipsen
- Start
- May 2009
- Primary completion
- May 2013
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Syndrome (CS) comparing Lanreotide Autogel with Placebo (2 arms). Primary endpoint: Percentage of Days With Subcutaneous Octreotide as Rescue Medication at 16 weeks. Started May 2009; status: completed.
02
Drugs
lanreotide
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT00774930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774930.